Overview

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
AstraZeneca
United States Department of Defense